(R)-(+)-Thalidomide
(R)-(+)-Thalidomide structure
|
Common Name | (R)-(+)-Thalidomide | ||
|---|---|---|---|---|
| CAS Number | 2614-06-4 | Molecular Weight | 258.22900 | |
| Density | 1.503g/cm3 | Boiling Point | 509.7ºC at 760 mmHg | |
| Molecular Formula | C13H10N2O4 | Melting Point | 269-271ºC | |
| MSDS | Chinese USA | Flash Point | 262.1ºC | |
| Symbol |
GHS07, GHS08 |
Signal Word | Danger | |
|
Thalidomide is an inhibitor of angiogenesis.
Proc. Natl. Acad. Sci. U. S. A. 91 , 4082, (1994) Thalidomide is a potent teratogen causing dysmelia (stunted limb growth) in humans. We have demonstrated that orally administered thalidomide is an inhibitor of angiogenesis induced by basic fibroblast growth factor in a rabbit cornea micropocket assay. Exper... |
|
|
Thalidomide inhibits the replication of human immunodeficiency virus type 1.
Proc. Natl. Acad. Sci. U. S. A. 90 , 5974-5878, (1993) Thalidomide, a selective inhibitor of tumor necrosis factor alpha (TNF-alpha) synthesis, suppresses the activation of latent human immunodeficiency virus type 1 (HIV-1) in a monocytoid (U1) line. The inhibition is dose dependent and occurs after exposure of t... |
|
|
Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell death.
Mol. Cell. Biol. 28(2) , 529-538, (2008) Thalidomide, a drug used for the treatment of multiple myeloma and inflammatory diseases, is also a teratogen that causes birth defects, such as limb truncations and microphthalmia, in humans. Thalidomide-induced limb truncations result from increased cell de... |
|
|
Thalidomide resistance is based on the capacity of the glutathione-dependent antioxidant defense.
Mol. Pharm. 5(6) , 1138-1144, (2008) Thalidomide as an effective treatment for multiple myeloma and leprosy has also caused birth defects in thousands of children five decades ago particularly in Europe. Thus its use in humans remains limited. The rapid and fatal approval of thalidomide at that ... |